baber/WOPTO huggingface dataset:
Patent NZ-545840-A (NZ)
Title: Catch device as part of a fall protection for ladders and similar climbing devices
Inventor: KRAUSS MARKUS
IPC: A62B1/14
Filed: 2004-09-13
Abstract: A fall arrester is disclosed. The fall arrestor, which forms part of a fall protection system for ladders and similar climbing routes and can be inserted into a guide rail with a C-profile, where the guide rail defines a longitudinal axis. The fall arrester comprises a body defining a front end and a rear end of the fall arrester, and at least a first and a second pair of rolls which are arranged on the body and which are adapted to run inside the guide rail. The rolls have an axis of rotation wherein the first pair of rolls are rigid against the body and the second pair of rolls are swivellable about an axis, which runs at right angles to the longitudinal axis of the guide rail and to the axis of rotation of this pair of rolls.
Patent NZ-546506-A (NZ)
Title: Surgical clip applicator with a visual indicator to indicate an intermediate position at which the surgical clip is half closed
Inventor: BRIGHT CHARLES EDWARD
Filed: 2004-10-15
Abstract: This discloses a surgical pin applicator 10 comprising a barrel portion 12 with a handle portion 14 attached to it. The barrel portion 12 comprises means for holding a surgical clip and the handle 14 comprises trigger means 16. The trigger means 16 operates to effect closure of a surgical clip held within the barrel 12 by movement of the trigger 16 from a first position to a second position when the applicator 10 operates to effect closure of the clip. The trigger 16 comprises a visual indicator means indicative of an intermediate trigger position at which the surgical clip held in the barrel 12 is closed to a half closed position.
Patent NZ-547193-A (NZ)
Title: 6-Substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
Inventor: MABIRE DOMINIQUE JEAN-PIERRE
IPC: C07D241/44
Filed: 2004-11-18
Abstract: A compound of general formula (I) which is suitable for use as a medicament to treat for example cancer, to enhance chemosensitisation, radiosensitisation and for use in combination with a chemotherapeutic agent.
Patent NZ-551889-A (NZ)
Title: Device for preventing cribbing or sucking in horses
Inventor: BARCLAY RICHARD
IPC: A01K29/00
Filed: 2005-05-21
Abstract: An electric shock device for attachment to a horse or other equine animal to discourage wind-sucking behaviour is provided. The device includes: an attachment for locating the device on the neck of the animal including a substantially rigid portion and a flexible, adjustable portion; an electrical charge source device operatively connected to the attachment, capable of delivering an electric pulse upon activation; electrode means electrically connected to the electric charge source to apply an electric pulse from the electric charge source to the animal; and activation means activated in response to the performance by the animal of the wind-sucking behaviour alone, including a lever member hinged to the rigid portion at one end and configured to translate the movement of the animal associated with wind-sucking alone into a movement of sufficient force or of the type required to activate the electric charge source.
Patent NZ-555088-A (NZ)
Title: N-[(4-cyclohexyl)-phenyl]-[1,2,4]triazole-3,5-diamines useful as inhibitors of protein kinases
Inventor: DAVIES ROBERT J
IPC: C07D401/04
Filed: 2005-10-21
Abstract: Disclosed is a compound of formula (I), wherein the substituents are as defined in the specification. The compounds are useful in the treatment of allergic disorders, proliferative disorders, autoimmune disorders, conditions associated with organ transplant, inflammatory disorders, immunologically mediated disorders and destructive bone disorders.
Patent NZ-564086-A (NZ)
Title: Synergistic blends of (alkyl) naphthalene formaldehyde condensate sulfonates and lignosulfonates useful in agrochemical formulations
Inventor: ALEXANDER MARK
IPC: A01N25/04
Filed: 2006-05-29
Abstract: Disclosed is a process for preparing a dispersing agent composition in the form of a free flowing powder, said process comprising a step of co-drying a) at least one lignin sulfonate, and b) at least one naphthalene formaldehyde condensate sulfonate, said process comprising the sub-steps of blending an aqueous mixture of a) and an aqueous mixture of b), in order to obtain a blended aqueous mixture of components a) and b), followed by drying said blended aqueous mixture in order to obtain said improved dispersing agent composition in the form of a free-flowing powder and their use in agrochemical formulations.
Patent NZ-569289-A (NZ)
Title: Carton with handle
Inventor: GOMEZ JEAN-MANUEL
IPC: B65D71/00
Filed: 2006-12-26
Abstract: A carton 190, comprises a top panel 170 including a first top panel 40 and a second top panel 50, a bottom panel, a first side panel 20, a second side panel 20, a first end panel 180, a second end panel 180, and an extendable handle 150 formed in the first and second top panels 40,50 where a first end 102 of the handle 150 is detachably connected to the first end panel 180 and a second end of the handle 150 is detachably connected to the second end panel 180. When the handle 150 is pulled upwards the first end 102 of the handle 150 detaches from the first end panel 180 and the second end of the handle 150 detaches from the second end panel 180, so the handle 150 separates from and moves upwards away from the top panel 170.
Patent NZ-574148-A (NZ)
Title: Phenylephrine liquid formulations comprising polyethylene glycol with low aldehyde content
Inventor: BUBNIS WILLIAM
IPC: A61K31/137
Filed: 2007-07-11
Abstract: Disclosed is an oral liquid pharmaceutical composition comprising: (a) phenylephrine or a pharmaceutically acceptable salt thereof; and (b) substantially aldehyde-free polyethylene glycol, wherein the substantially aldehyde-free polyethylene glycol has less than 10 ppm total aldehyde content and maintains said level of aldehyde content for at least one year; (c) a second active agent selected from an analgesic, a decongestant, an expectorant, an anti-tussive, an antipyretic, an anti-inflammatory agent, a cough suppressant and an antihistamine; and (d) a buffering agent which maintains a pH below 5.4 in the composition. Also disclosed is the use of the phenylephrine formulation for treating a cold, flu, or allergy in mammals.
Patent NZ-574153-A (NZ)
Title: Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs
Inventor: TRAVIS KIM ZACHARY
IPC: A61K31/4155
Filed: 2006-08-18
Abstract: The disclosure relates to, inter alia, the use of a compound of formula (I), which is capable of inhibiting 4-hydroxyphenylpyruvate dioxygenase (HPPD) in an animal in the manufacture of a medicament for use in the treatment and/or prevention of depression. The disclosure also provides for the use of a compound capable of inhibiting HPPD in an animal in the manufacture of a medicament for use in the treatment of the withdrawal symptoms associated with an addictive drug which causes dopamine dependant associative learning disorders in said animal. In a particular embodiment said HPPD inhibitor is selected from the group consisting of the compound depicted as compound 1, 2, and 3.22.
Patent NZ-575662-A (NZ)
Title: Removable barricade system with sleeves that fit over bollards
Inventor: GELFAND MATTHEW A
IPC: E04H17/00
Filed: 2007-09-19
Abstract: A removable barricade system (200) with three sleeves (300A, 300B, 300C) that fit over three bollards (not shown), a horizontal barrier (10), and a latch (not shown). The horizontal barrier (10), which can be a net (10), is attached to the sleeves (300A, 300B, 300C). The net is longer than the distance between bollards, so it blocks the area between the bollards. The latch (not shown) puts tension on the net and gathers the extra length.
Patent NZ-577133-A (NZ)
Title: Inducing b-party defined behaviours in a-party communications by distribution of user interfaces
Inventor: JAMES ROBERT GEOFFREY
IPC: H04M3/42
Filed: 2007-10-31
Abstract: A system for inducing B-party defined behaviour in an A-party communications end-point and a method for inducing B-party defined behaviour in an A-party communications end-point are disclosed. The system includes one or more network accessible entities configured to store a user interface encoding one or more B-party defined or selected behaviours; and communicate the user interface to the A party communications end-point; and at least one A-party communications end-point configured to receive the user interface; invoke the user interface in response to one or more triggers; and interpret the user interface to induce a resultant behaviour. Also disclosed is a user interface for inducing B-party defined or selected behaviour in an A-party communications end-point. The user interface encoding one or more B-party defined behaviours and including one or more software or data objects to cause invocation of the user interface at the A-party communications end-point in response to one or more triggers; and interpretation of the user interface at the A-party communications end-point to induce a resultant behaviour.
Patent NZ-577733-A (NZ)
Title: Joinery assembly with corner joint that fits inside two elongate members and is crimped to provide support
Inventor: BAINES IAN PAUL
IPC: E06B7/12
Filed: 2010-05-13
Abstract: A corner joint for a frame includes a body 51 and leg portions projecting from the body so that the leg portions can be slipped into the ends 60 of the frame members 53, 54 toward the outside of the frame members to join the frame members at a corner 52. The body has notches 42, 43 in opposing directions in each leg portion that in use are covered by each elongate frame member when the corner joint is assembled, so that a portion of the elongate frame member can be crimped into each notch to hold the joint firm.
Patent NZ-580626-A (NZ)
Title: Admixing a pigment and dye to a binder, the dye to indicate attempted chemical or mechanical alteration to a document
Inventor: RILEY MICHAEL R
IPC: G03G9/08
Filed: 2008-04-23
Abstract: Disclosed is a toner (102) for printing documents that are difficult to chemically or physically forge and that are readily easy to visually verify. The toner (102) includes a colorant, a fluorescent pigment and a migration enhancing agent. The colorant is used for printing an image on a surface of a document. Under normal lighting, the fluorescent pigment is masked by the colorant. However, when irradiated by black or ultra-violet light, the fluorescent pigment creates a visible image on the first surface (106) of a substrate (104). An image formed using the toner (102) is readily verified by comparing the colorant-formed image and the dye-formed image. In addition, if a solvent is used in an attempt to alter the printed image on the substrate (104), the dye (110) migrates or diffuses to indicate tampering with the document.
Patent NZ-580951-A (NZ)
Title: Therapeutic compositions
Inventor: GOWAN WALTER J JR
IPC: A61K9/16
Filed: 2006-04-27
Abstract: Provided is a method of formulating an orally administered therapeutic agent for increased bioavailability in a subject, the method comprising (a) combining in a pharmaceutical composition a biopolymer, a therapeutic agent and an absorption enhancer consisting of a polyoxyethylene alkyl ether of the formula R(OCH2CH2)nOH with R being an alkyl moiety having from 12 to 22 carbons and n being 4 to 23, in the absence of at least one of a triglyceride and a fatty acid; and (b) formulating a therapeutically effective amount of the pharmaceutical composition in a dosage form suitable for oral administration to the subject; wherein the biopolymer is selected from the group consisting of: carrageenans, carbopols, polycarbophils, cellulosics, pectins, chondroitin sulfate, polymethacrylic acid, xylan, hyaluronic acid, chitin, chitosan, sodium alginates, polysaccharides, polypropylene glycols, polyethylene glycols, polyacetates, liposomes, fatty acid complexes, cyclodextrins, cycloamyloses, clathrates, cycloalkyl amyloses, polyxylose, gellan gums and polylactic acids; and wherein the therapeutic agent is selected from a glycopeptide, a penicillin, a monobactam, an oxazolidinone, a lipopeptide, a carbapenem, an aminoglycoside, a beta-lactam inhibitor or combinations thereof.
Patent NZ-589631-A (NZ)
Title: Espresso coffee machine with selection device for communicating the infusion receptacle with a hot water feed pipe, an outlet pipe or both.
Inventor: BAMBI PIERO
IPC: A47J31/46
Filed: 2008-04-30
Abstract: An espresso coffee machine comprises a boiler and a pump for feeding hot water under pressure to one or more brew groups (1). Each brew group (1) comprises a receptacle (24) for infusing a predetermined dose of ground coffee, a hot water feed pipe and an outlet pipe (40). Manual operating means (30) are provided at the inlet of each brew group for selectively putting the coffee powder receptacle (24) in fluid communication with the water feed pipe, with the outlet pipe (40) or with both the pipes in order to preinfuse the coffee powder at a lower pressure.
Patent NZ-594800-A (NZ)
Title: Method and apparatus for modifying a service policy setting of an end-user device
Inventor: RALEIGH GREGORY G
IPC: H04W4/50
Filed: 2010-01-27
Abstract: A method and a system for modifying a service policy setting of an end-user device are disclosed. The system comprises means for receiving a report from an end-user device over a service control link; means for determining, based on the report, that a particular service policy setting of the end-user device needs to be modified and means for sending configuration information over the service control link to modify the particular service policy setting with the sending in response to determining that the particular service policy setting needs to be modified. The report comprises information about a device service state and the particular service policy setting is stored in a protected partition of the end-user device and the particular service policy setting is associated with a service plan that provides for access to a network data service over a wireless access network and configured to assist in controlling one or more communications between the end-user device and the wireless access network. The protected partition is configured to deter or prevent unauthorized modifications to the particular service policy setting.
Patent NZ-595903-A (NZ)
Title: A novel formulation of metaxalone
Inventor: NORRET MARCK
IPC: A61K9/14
Filed: 2010-04-23
Abstract: 595903 The present disclosure relates to methods for producing particles of metaxalone using dry milling processes as well as compositions comprising metaxalone, medicaments produced using metaxalone in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of metaxalone administered by way of said medicaments.
Patent NZ-604089-A (NZ)
Title: Multivalent glycopeptide constructs and uses thereof
Inventor: DANISHEFSKY SAMUEL J
IPC: C07K1/00
Filed: 2011-06-10
Abstract: Disclosed is the use of a therapeutically effective amount of an immunogenic glycoconjugate in the manufacture of a medicament for treating ovarian cancer in a subject suffering therefrom, wherein the immunogenic glycoconjugate comprises a multi-antigenic glycopeptide having a peptidic backbone made up of at least five amino acid residues, wherein five or more of said amino acids independently have a structure as defined in the complete specification.
Patent NZ-610151-A (NZ)
Title: Salts and crystalline forms of an apoptosis-inducing agent
Inventor: CATRON NATHANIEL D
IPC: C07D471/04
Filed: 2011-11-21
Abstract: Disclosed are salts and crystalline forms of the compound 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl} piperazin-1-yl)-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide (abstract figure). The crystalline forms include anhydrates, hydrates, dichloromethane solvate, ethyl acetate solvate, acetonitrile solvate, acetone and tetrahydrofuran. The salts include hydrochloride and sulfate. The disclosure also relates to pharmaceutical compositions comprising the salts and crystalline forms and methods for treating diseases characterised by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein by using the salts and crystalline forms herein.
Patent NZ-610669-A (NZ)
Title: Method and system for saccharifying and fermenting a biomass feedstock
Inventor: MEDOFF MARSHALL
IPC: C12P7/14
Filed: 2010-11-18
Abstract: Disclosed is a method comprising: Placing a liquid medium comprising water and an unsaccharified electron beam irradiated lignocellulosic feedstock in a vessel; saccharifying the feedstock in a liquid medium in a vessel, while mixing with a jet mixer comprising a plurality of jet flow agitators, to form a sugar solution and in the same vessel converting the sugar solution to a product, utilizing an enzyme and/or a microorganism, wherein the irradiated lignocellulosic feedstock has been irradiated with a does of at least 10 Mrad.
Patent NZ-616926-A (NZ)
Title: Diazonamide analogs
Inventor: WEI QI
IPC: C07F9/6561
Filed: 2012-04-15
Abstract: Provided are macrocyclic diazonamide A analogue compounds of the general formula (I), wherein the variables are as defined in the specification. The compounds disrupt the mitotic spindle. The compounds may be useful in the treatment of cancer.
Patent NZ-619471-A (NZ)
Title: Compact desiccant cooling system
Inventor: WHITE STEPHEN DAVID
IPC: F24F3/14
Filed: 2012-06-04
Abstract: A solid desiccant cooling system includes, means (13, 17) defining a first pathway (11) for air to be cooled and a second pathway (15) for regeneration air, and structure (14) retaining a mass of solid desiccant for cyclic movement between a first location (14a), in which the solid desiccant lies in the first pathway for dehumidifying the air to be cooled by adsorption of moisture to the desiccant, and a second location (14b) in which the solid desiccant lies in the second pathway for the regeneration air to take up moisture therein as water vapour. An air heater arrangement (40) is provided in the second pathway upstream of the second location for heating the regeneration air, and an air cooler arrangement (18), independent of the air heater arrangement, is provided in the first pathway downstream of the first location. An air delivery device (50) is coupled to both pathways whereby the device is operable to deliver air along both pathways from a common intake, wherein the pressure drop along the respective pathways is of a similar magnitude. Also disclosed are a method of operating a solid desiccant cooling cycle, and a control system for a solid desiccant cooling system.
Patent NZ-626353-A (NZ)
Title: Stabilized pharmaceutical formulations of a potent hcv inhibitor
Inventor: BRAUN MATHIAS
IPC: A61K47/44
Filed: 2013-01-10
Abstract: Described are various methods for stabilizing pharmaceutical formulations of a specific Hepatitis C Viral (HCV) inhibitor of formula (I) against the formation of a particular genotoxic degradation product. Such methods include temperature control, moisture control, excipient control, capsule shell control, basification and a reconstitution approach.
Patent NZ-631691-A (NZ)
Title: Innovative clothesline system and method of use
Inventor: BRIAN NORMAN HUDSON
IPC: D06F57/00
Filed: 2014-03-04
Abstract: A clothesline system with a circular clothesline frame (3) and a protective cover (8, 12) is disclosed. The cover (8, 12) opens in a rotational fashion to cover, or at least partially cover, the clothesline frame. The frame (3) may be used as a track to support the cover (8, 12) with the clothes lines extending inwards from the frame (3) and in the same plane as the frame.
Patent NZ-631825-A (NZ)
Title: Heating panel
Inventor: FILIPE LIM
IPC: H05B3/56
Filed: 2014-09-12
Abstract: Disclosed is a heating panel (10) comprising a base panel. The base panel having a channel (14) formed into a face of the base panel and an electric element (16) is laid to extend along the channel. The heating panel may further comprise a portion of mesh (28) material covering the channel. The electric element may be in the form of an insulated wire. The channel may form a serpentine path (as shown) across a major portion of the width and height of the base panel. The panel can contain a tilt switch such that the heating power is stopped if the panel falls over, allowing the panel to be used as a free standing heater, not limited to a wall mounting arrangement.
Patent NZ-716156-A (NZ)
Title: Novel indolizine derivatives useful as bcl-2 inhibitors, method for the production thereof and pharmaceutical compositions containing same
Inventor: STARCK JÉRÔME-BENOÎT
IPC: C07D498/04
Filed: 2014-07-22
Abstract: The invention provides indolizine derivatives of formula (I): wherein Ra, Rb, Rc, Rd, T, R3, R4, R5, X, Y and Het are as defined in the description, useful as Bcl-2 inhibitors, method for the production thereof and pharmaceutical compositions containing same for the treatment of cancers, auto-immune diseases and diseases of the immune system.
Patent NZ-720384-A (NZ)
Title: Recombinant glycoproteins and uses thereof
Inventor: LEE KAREN
IPC: C12N9/40
Filed: 2014-10-22
Abstract: Provided herein are recombinant glycoproteins (e.g., recombinant human α-galactosidase-A proteins) with an altered (e.g., improved) glycosylation profile, and pharmaceutical compositions and kits including one or more of these proteins. Also provided are methods of generating a mammalian cell useful for recombinant expression of a glycoprotein (e.g., recombinant human α-galactosidase-A), methods of producing recombinant glycoproteins, and methods of treatment that include administering to a subject at least one of the recombinant glycoproteins (e.g., recombinant human α-galactosidase-A protein).
Patent NZ-726256-A (NZ)
Title: Methods for treating pulmonary non-tuberculous mycobacterial infections
Inventor: EAGLE GINA
IPC: A01N43/04
Filed: 2015-05-15
Abstract: Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.